Academic Journal
Q1Journal of Addiction Medicine
About Journal of Addiction Medicine
About Journal of Addiction Medicine
Journal of Addiction Medicine is a peer-reviewed scholarly journal published by Lippincott Williams and Wilkins (United States). It focuses on Q1. Publication coverage spans 2007-2026.
Key indicators: ISSN 1932-0620, 1935-3227; H-index 67.
Understanding This Journal's Metrics
Journal metrics help researchers assess fit, but they must be interpreted in context:
- H-index (67): Strong citation impact — 67 articles cited at least 67 times each, reflecting solid influence.
Publishing in Journal of Addiction Medicine
An established venue in its field. The journal welcomes solid, well-executed research. Ensure your manuscript fits the stated scope and follows author guidelines carefully.
- Scope fit: Confirm your research aligns with Q1. Off-scope manuscripts are typically desk-rejected quickly.
- Author guidelines: Follow formatting, reference style, and article-type requirements exactly — non-compliant manuscripts may be returned without review.
Is This Journal Right for Your Paper?
- Audience match: Will the journal's readers cite and build on your findings?
- Timeline: Higher-tier journals mean longer review and higher rejection risk. Balance prestige against your schedule.
- Indexing: Confirm indexing in Web of Science, Scopus, and PubMed (if biomedical) meets your institutional requirements.
- Open access needs: Check funder mandates and whether the journal offers compliant OA options.
Frequently Asked Questions
What is the ISSN of Journal of Addiction Medicine?
1932-0620, 1935-3227.
Who publishes Journal of Addiction Medicine?
Lippincott Williams and Wilkins.
What are Journal of Addiction Medicine's metrics?
H-index 67.
Is Journal of Addiction Medicine peer-reviewed?
Yes — it is a peer-reviewed scholarly journal indexed in major academic databases.
Source-backed journal facts
Topics in published research
Opioid Use Disorder Treatment; Substance Abuse Treatment and Outcomes; HIV, Drug Use, Sexual Risk; Prenatal Substance Exposure Effects; Forensic Toxicology and Drug Analysis; Pain Management and Opioid Use.
OpenAlex classifies topics from published works. These topics are not the publisher’s official aims and scope.
Source: OpenAlex source record. Retrieved 2026-10-03. Source record updated 2026-10-02. OpenAlex metrics are different from SCImago metrics and the Clarivate Journal Impact Factor.
Journal Metrics
Quartile, SJR and the listed SCImago H-index use the 2025 imported SCImago dataset. A quartile may vary by subject category. Values without a source or reporting year are unverified historical entries. Verify the current Journal Impact Factor with Clarivate or the publisher before using it.
Aims & Scope
The publisher’s official aims and scope have not yet been verified for this profile. Use the journal website to check subject fit and accepted article types before submitting.
Recent Research Articles
Latest publications matched automatically by ISSN.
Kratom-labeled Products in the US Compared With Traditionally Consumed Natural Kratom in Southeast Asia
Thiruventhan Karunakaran, Kasinather Vicknasingam, Marek C Chawarski
2026-10-20 · DOI: 10.1097/adm.0000000000001785Managing the Hospital Capacity Challenges of Medetomidine Withdrawal: A Retrospective Report of Dexmedetomidine Use in Intermediate Care Units
Philip A. Durney, Dennis Goodstein, Elise Paquin, Gamal Fitzpatrick et al.
2026-10-09 · DOI: 10.1097/adm.0000000000001789Ketamine Use Disorder and Entrenchment of Delusional Beliefs: A Case Report
Samuel (Sukmin) Yang, Rachel Goud, Jeremy Weleff
2026-10-05 · DOI: 10.1097/adm.0000000000001788Liver Transplantation Outcomes in Patients With and Without Alcohol Use Disorder Diagnosis: Evidence From a Nationwide Cohort Study
Yu Si Chen, Paola Lavin, Samuel Cyr, Kellie Elkrief et al.
2026-10-01 · DOI: 10.1097/adm.0000000000001777Visiting Nurse Services-facilitated Outpatient Low-dose Buprenorphine Initiation and Engagement in Severe Mental Illness and Ongoing Fentanyl Use: A Case Report
Fabiola Arbelo Cruz, Jean C. Castillo, Nicolas Pérez Palmer
2026-09-28 · DOI: 10.1097/adm.0000000000001784Scoping Review of Implementation Science in Digital Intervention Research for Substance Use Disorders
Deepika Rao, Madison K. Clement, Caitlin M. Reardon, Lisa Saldana et al.
2026-09-28 · DOI: 10.1097/adm.0000000000001780Clinical Outcomes of a 3-day Benzodiazepine Detoxification Protocol With Continuous Subcutaneous Flumazenil Infusion: An Open-label Pilot Study
Damian A. Visser, Erik P. Paling, Daphne S. Everaerd, Nens van Alfen et al.
2026-09-25 · DOI: 10.1097/adm.0000000000001786When Buprenorphine Was Not Enough: Methadone Treatment of Tianeptine Use Disorder
David Tyler Coyle, Morgan Kitano, Susan Calcaterra
2026-09-21 · DOI: 10.1097/adm.0000000000001782Insights About Nitazene Use From Self-reported Experiences on Reddit Obtained Using Natural Language Processing
Pranav Sompalle, Jeanmarie Perrone, Rachel Wightman, Jennifer Love et al.
2026-09-18 · DOI: 10.1097/adm.0000000000001760In-Hospital Substance Use: A Qualitative Study of Patient and Staff Experiences
Taylor Baisey, Madeleine Peitz, Elyssa Samayoa, Kelly Knight et al.
2026-09-16 · DOI: 10.1097/adm.0000000000001776Magnitude and Abstinence Trajectories of Neurocognitive Deficits in Methamphetamine Use Disorder: A Systematic Review and Meta-analysis
Lu Cao, Yi Xie, Xiao-Fei Cheng, Ting-Wan Xu et al.
2026-09-15 · DOI: 10.1097/adm.0000000000001778“Rhino Tranq” in Connecticut—Prevalence of Medetomidine in the Fentanyl Supply Varies by Data Source
Katherine Hill, Elizabeth Znamierowski, Cameron Breen, River Rose et al.
2026-09-15 · DOI: 10.1097/adm.0000000000001779Changes in Alcohol Use are Associated With Changes in Depression Severity Among People With HIV
Mindy Dai, Joseph A.C. Delaney, Geetanjali Chander, Heidi M. Crane et al.
2026-09-15 · DOI: 10.1097/adm.0000000000001769The Overlapping Symptoms of Perimenopause and Opioid Withdrawal: When Hormone Therapy is “Even more Important for My Recovery than My Methadone”
McKenna Klausner, Daniel Roche, Katrina Mark
2026-09-11 · DOI: 10.1097/adm.0000000000001765Treatment Discontinuation and Barriers and Facilitators to Retention Among Individuals Initiating Buprenorphine for Opioid Use Disorder: A Longitudinal Cohort Study
Melissa N. Poulsen, Michelle L. Truong, Jasmine K. Pabla, Amy Poissant et al.
2026-09-07 · DOI: 10.1097/adm.0000000000001775Addiction Consult Service Associated With Improved Rates of 30-day Treatment Engagement After Emergency Department and Hospital Discharge: A Propensity-weighted Analysis
Erik S. Anderson, Lauren Sirey, Andrea Jakubowski, Megan Heeney et al.
2026-09-07 · DOI: 10.1097/adm.0000000000001773Opioid Use Disorder Outcomes Following Inpatient Opioid Withdrawal Management
Genie L. Bailey, Joshua D. Lee, Edward V. Nunes, Babak Tofighi et al.
2026-09-04 · DOI: 10.1097/adm.0000000000001710National Quality Measure Fails to Capture Most Emergency Department Patients With Opioid Use Disorder
Erik S. Anderson, Megan Heeney, Evan Rusoja, Hillary Katsin et al.
2026-09-04 · DOI: 10.1097/adm.0000000000001774Outpatient Direct Initiation of Injectable Buprenorphine From Methadone: A Case Series
Daniel Liauw, Ram Sundaresh, Dinah Applewhite, Jessica R. Gray et al.
2026-09-03 · DOI: 10.1097/adm.0000000000001770Impact of Addiction Consult Service on Alcohol Use Disorder Medications and Postdischarge Outcomes
Thomas J. Reese, Kristopher A. Kast, David Marcovitz, Clayton Korson et al.
2026-09-03 · DOI: 10.1097/adm.0000000000001762Reviews
Community Reviews
Version History
October 9, 2026 at 7:45 pm
September 25, 2026